Atara Biotherapeutics Q4 EPS $(0.56) Misses $(0.48) Estimate, Sales $4.25M Miss $11.55M Estimate
Portfolio Pulse from Benzinga Newsdesk
Atara Biotherapeutics (NASDAQ:ATRA) reported Q4 earnings with a loss of $(0.56) per share, missing the $(0.48) estimate, and sales of $4.25M, missing the $11.55M estimate. Despite these misses, the company saw a significant increase in sales compared to the same period last year.
March 28, 2024 | 3:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Atara Biotherapeutics reported lower than expected Q4 earnings and sales, but showed a significant year-over-year sales increase.
The miss on both earnings per share and sales estimates is likely to negatively impact investor sentiment and the stock price in the short term. However, the significant increase in sales year-over-year could provide some positive outlook, mitigating the negative impact to some extent.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100